Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes

Henri K Parson, Meredith A Bundy, Charlotte B Dublin, Amanda L Boyd, James F Paulson, Aaron I VinikLeonard R. Strelitz Diabetes Center, Department of Internal Medicine Eastern Virginia Medical School, Norfolk, Virginia, USAAbstract: Rosuvastatin is known to reduce low-density lipoprotein (LDL)-chole...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Henri K Parson, Meredith A Bundy, Charlotte B Dublin, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/c3f5e8044c7f43f98bc197db1d733593
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c3f5e8044c7f43f98bc197db1d733593
record_format	dspace
spelling	oai:doaj.org-article:c3f5e8044c7f43f98bc197db1d7335932021-12-02T08:24:58ZPleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes1178-7007https://doaj.org/article/c3f5e8044c7f43f98bc197db1d7335932010-01-01T00:00:00Zhttp://www.dovepress.com/pleiotropic-effects-of-rosuvastatin-on-microvascular-function-in-type--a3926https://doaj.org/toc/1178-7007Henri K Parson, Meredith A Bundy, Charlotte B Dublin, Amanda L Boyd, James F Paulson, Aaron I VinikLeonard R. Strelitz Diabetes Center, Department of Internal Medicine Eastern Virginia Medical School, Norfolk, Virginia, USAAbstract: Rosuvastatin is known to reduce low-density lipoprotein (LDL)-cholesterol and improve endothelial function. In addition to lipid-lowering, statins may exert pleiotropic (nonlipid lowering) effects on microvascular function. We compared the neurophysiological and vascular responses of dietary control and treatment with 10 mg of rosuvastatin in 16 subjects with neuropathy and established type 2 diabetes. Skin blood flow (SkBF) measurements were measured at baseline, after 18 weeks of diet, and after 18 weeks of diet and treatment with rosuvastatin in response to local warming and ischemia reperfusion. The study results show that total cholesterol (196.50 &plusmn; 8.02 to 134.88 &plusmn; 10.86 mg/dL) and LDL-cholesterol (114 &plusmn; 10.4 to 63.4 &plusmn; 8.48 mg/dL) decreased significantly after 18 weeks of rosuvastatin, but not after 18 weeks of diet. Neuropathy scores decreased from 8.34 &plusmn; 1.26 at baseline to 6.00 &plusmn; 0.90 after rosuvastatin treatment. Basal SkBF was significantly different from baseline, 6.81 &plusmn; 0.42 to 9.92 &plusmn; 0.78 after rosuvastatin treatment (P &le; 0.001). These results indicate that rosuvastatin therapy positively changed basal SkBF and measures of neurovascular function. Although there was a profound lipid lowering, it is not clear that this mediated the increases in SkBF and decreases in neuropathy scores.Keywords: neurovascular function, rosuvastatin, diabetes Henri K ParsonMeredith A BundyCharlotte B Dublinet alDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2010, Iss default, Pp 19-26 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Henri K Parson Meredith A Bundy Charlotte B Dublin et al Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes
description	Henri K Parson, Meredith A Bundy, Charlotte B Dublin, Amanda L Boyd, James F Paulson, Aaron I VinikLeonard R. Strelitz Diabetes Center, Department of Internal Medicine Eastern Virginia Medical School, Norfolk, Virginia, USAAbstract: Rosuvastatin is known to reduce low-density lipoprotein (LDL)-cholesterol and improve endothelial function. In addition to lipid-lowering, statins may exert pleiotropic (nonlipid lowering) effects on microvascular function. We compared the neurophysiological and vascular responses of dietary control and treatment with 10 mg of rosuvastatin in 16 subjects with neuropathy and established type 2 diabetes. Skin blood flow (SkBF) measurements were measured at baseline, after 18 weeks of diet, and after 18 weeks of diet and treatment with rosuvastatin in response to local warming and ischemia reperfusion. The study results show that total cholesterol (196.50 &plusmn; 8.02 to 134.88 &plusmn; 10.86 mg/dL) and LDL-cholesterol (114 &plusmn; 10.4 to 63.4 &plusmn; 8.48 mg/dL) decreased significantly after 18 weeks of rosuvastatin, but not after 18 weeks of diet. Neuropathy scores decreased from 8.34 &plusmn; 1.26 at baseline to 6.00 &plusmn; 0.90 after rosuvastatin treatment. Basal SkBF was significantly different from baseline, 6.81 &plusmn; 0.42 to 9.92 &plusmn; 0.78 after rosuvastatin treatment (P &le; 0.001). These results indicate that rosuvastatin therapy positively changed basal SkBF and measures of neurovascular function. Although there was a profound lipid lowering, it is not clear that this mediated the increases in SkBF and decreases in neuropathy scores.Keywords: neurovascular function, rosuvastatin, diabetes
format	article
author	Henri K Parson Meredith A Bundy Charlotte B Dublin et al
author_facet	Henri K Parson Meredith A Bundy Charlotte B Dublin et al
author_sort	Henri K Parson
title	Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes
title_short	Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes
title_full	Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes
title_fullStr	Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes
title_full_unstemmed	Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes
title_sort	pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/c3f5e8044c7f43f98bc197db1d733593
work_keys_str_mv	AT henrikparson pleiotropiceffectsofrosuvastatinonmicrovascularfunctionintype2diabetes AT meredithabundy pleiotropiceffectsofrosuvastatinonmicrovascularfunctionintype2diabetes AT charlottebdublin pleiotropiceffectsofrosuvastatinonmicrovascularfunctionintype2diabetes AT etal pleiotropiceffectsofrosuvastatinonmicrovascularfunctionintype2diabetes
_version_	1718398567322746880

Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes

Ejemplares similares